Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome

Author:

Rola Piotr12ORCID,Włodarczak Adrian13ORCID,Włodarczak Szymon3ORCID,Barycki Mateusz2ORCID,Szudrowicz Marek3ORCID,Łanocha Magdalena4ORCID,Furtan Łukasz2ORCID,Woźnica Katarzyna5ORCID,Kulczycki Jan Jakub3ORCID,Jaroszewska-Pozorska Joanna3,Kędzierska Michalina6ORCID,Doroszko Adrian7ORCID,Lesiak Maciej8ORCID

Affiliation:

1. Witelon Collegium State University, 59-220 Legnica, Poland

2. Department of Cardiology, Provincial Specialized Hospital in Legnica, 59-220 Legnica, Poland

3. Department of Cardiology, The Copper Health Centre (MCZ), 59-300 Lubin, Poland

4. Adalbert’s Hospital, 61-144 Poznan, Poland

5. Faculty of Mathematics and Information Science, Warsaw University of Technology, 00-662 Warsaw, Poland

6. Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland

7. Clinical Department of Internal and Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-556 Wroclaw, Poland

8. 1st Department of Cardiology, Poznan University of Medical Sciences, 61-491 Poznan, Poland

Abstract

Background. Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of new biodegradable materials. This pilot study evaluates the performance of a magnesium bioresorbable scaffold (Magmaris, Biotronik, Germany) in comparison to the sirolimus‐eluting bioresorbable polymer stents (BP-SES) (Ultimaster, Terumo, Japan) in the NSTE-ACS setting. Methods. The population of this pilot comprised 362 patients assigned to one of two arms (193-Magmaris vs 169-Ultimaster). The data regarding the primary outcome comprised of death from cardiac causes, myocardial infarction, and stent thrombosis, along with target-lesion failure (TLF) and other clinical events was collected in the 1-yearfollow-up. Results. There were no statistically significant differences in clinical outcomes in the short term (30 days) or in the 1-yearfollow-up between both groups. Conclusion. At 12 months, there were no statistically significant differences between the Magmaris and Ultimaster for composed endpoints or the TLF.

Publisher

Hindawi Limited

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3